DarioHealthDRIO
DRIO
About: DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Employees: 202
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
5% more capital invested
Capital invested by funds: $4.51M [Q1] → $4.73M (+$213K) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1.87% less ownership
Funds ownership: 17.74% [Q1] → 15.87% (-1.87%) [Q2]
9% less funds holding
Funds holding: 43 [Q1] → 39 (-4) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for DRIO.
Financial journalist opinion
Based on 5 articles about DRIO published over the past 30 days
Neutral
PRNewsWire
1 day ago
DarioHealth Announces 20-to-1 Reverse Stock Split
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2025, under the Company's existing trading symbol "DRIO", but will trade under a new CUSIP Number, 23725P 308.
Negative
Zacks Investment Research
1 week ago
DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.06 per share a year ago.
Neutral
Seeking Alpha
2 weeks ago
DarioHealth Corp. (DRIO) Q2 2025 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Chen Franco-Yehuda - CFO, Treasurer & Secretary Erez Raphael - CEO & Director Steven C. Nelson - President & Chief Commercial Officer Zoe Harrison - Corporate Participant Conference Call Participants Theodore Rudd O'Neill - Litchfield Hills Research, LLC Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Second Quarter 2025 Results Conference Call.
Neutral
PRNewsWire
2 weeks ago
DarioHealth Reports Second Quarter 2025 Financial and Operating Results
Second quarter 2025 revenue was $5.4 million, compared to $6.3 million in the second quarter of 2024, and $6.8 million in the first quarter of 2025 - The Company believes that strong client momentum and strategic wins will offset decrease in revenues Approximately $5 million new committed annual recurring revenues ("CARR"); Plus $53 million pipeline of commercial opportunities, over $5 million of which is in final stages toward CARR - On track to secure total of 40 new clients by the end of 2025 Two new health plan clients are expected to represent multi-million-dollar opportunities for Dario over time, including a full-suite national health plan scheduled to launch in the second half of 2025 Gross margin increased to 55% compared to 44% in the second quarter of 2024 The core Business-to-Business-to-Consumer ("B2B2C") has been operating at approximately 80% gross margins on a non-GAAP basis since the first quarter of 2024 Operating loss in the second quarter of 2025 narrowed by 43% compared to the second quarter of 2024 Operating expenses for the second quarter of 2025 decreased by $6.8 million, or 36%, from the second quarter of 2024 with additional efficiencies anticipated through ongoing AI-driven process optimization Dario will host an investor conference call and webcast at 8:30 a.m. ET today NEW YORK , Aug. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the second quarter ended June 30, 2025, along with strategic and commercial updates.
Neutral
PRNewsWire
3 weeks ago
DarioHealth to Report Second Quarter 2025 Results on Tuesday, August 12, 2025
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK , Aug. 5, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 2nd quarter ended June 30 th, 2025 and will host a conference call and webcast at 8:30 a.m.
Neutral
PRNewsWire
2 months ago
Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide
Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution NEW YORK and SAN FRANCISCO , June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in value-based sleep health solutions, to bring the comprehensive care program to payers nationwide. The collaboration leverages the strengths of both companies to deliver a tiered, data-driven solution for improving member health outcomes, reducing healthcare costs, and enhancing productivity through the integration of behavioral health, sleep, and cardiometabolic care.
Neutral
PRNewsWire
2 months ago
Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings
Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions NEW YORK , June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that highlight the Company's platform's critical contribution in the digital health market.
Neutral
Seeking Alpha
3 months ago
DarioHealth Corp. (DRIO) Q1 2025 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Lara Dodo - Acting Chief Operating Officer Conference Call Participants Charles Yi - TD Securities David Grossman - Stifel Nicolaus Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth First Quarter 2025 Results Conference Call. At this time, all lines are in a listen-only mode.
Negative
Zacks Investment Research
3 months ago
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.20 per share a year ago.
Neutral
PRNewsWire
3 months ago
DarioHealth Reports First Quarter 2025 Financial and Operating Results
First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially. Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024 Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024 Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimization GAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 million Non-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5.8 million 14 new clients signed year-to-date, including a national health plan, regional plan, 12 employers, and two pharma companies Strategic platform expansion through GLP-1 prescribing (MediOrbis), behavioral health (Rula), and cardiometabolic support via a national benefit plan administrator GLP-1 solution expanded with virtual prescribing and integration into chronic condition programs Artificial Intelligence (AI) transformation underway, automating workflows, lowering costs, and enhanced operational scalability Refinanced debt and raised equity, strengthening balance sheet, extending cash runway and providing operating flexibility to drive strategic plans Dario remains on track to achieve operational cash flow breakeven run rate by the end of 2025 given existing account expansion, new contract wins and a pipeline of near-term opportunities Dario will host an investor conference call and webcast at 8:30 a.m.
Charts implemented using Lightweight Charts™